Related references
Note: Only part of the references are listed.In Vitro Activity of Cefepime-Taniborbactam against Carbapenemase-Producing Enterobacterales and Pseudomonas aeruginosa Isolates Recovered in Spain
Marta Hernandez-Garcia et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2022)
Infectious Diseases Society of America Guidance on the Treatment of AmpC β-Lactamase-Producing Enterobacterales, Carbapenem-Resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia Infections
Pranita D. Tamma et al.
CLINICAL INFECTIOUS DISEASES (2022)
Cefiderocol for the Treatment of Infections Due to Metallo-B-lactamase-Producing Pathogens in the CREDIBLE-CR and APEKS-NP Phase 3 Randomized Studies
Jean-Francois Timsit et al.
CLINICAL INFECTIOUS DISEASES (2022)
European Society of Clinical Microbiology and Infectious Diseases (ESCMID) guidelines for the treatment of infections caused by multidrug-resistant Gram-negative bacilli (endorsed by European society of intensive care medicine)
Mical Paul et al.
CLINICAL MICROBIOLOGY AND INFECTION (2022)
Comparative activity of newer β-lactam/β-lactamase inhibitor combinations against Pseudomonas aeruginosa from patients hospitalized with pneumonia in European medical centers in 2020
Helio S. Sader et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2022)
Multicenter surveillance of in vitro activities of cefepime-zidebactam, cefepime-enmetazobactam, omadacycline, eravacycline, and comparator antibiotics against Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii complex causing bloodstream infection in Taiwan, 2020
Shio-Shin Jean et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2022)
Effectiveness of ceftazidime-avibactam for the treatment of infections due to Pseudomonas aeruginosa
Laura Corbella et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2022)
Clinical exposure-response relationship of cefepime/taniborbactam against Gram-negative organisms in the murine complicated urinary tract infection model
Maxwell J. Lasko et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2022)
Comparative analysis of in vitro dynamics and mechanisms of ceftolozane/tazobactam and imipenem/relebactam resistance development in Pseudomonas aeruginosa XDR high-risk clones
Maria A. Gomis-Font et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2022)
Permeation of Fosfomycin through the Phosphate-Specific Channels OprP and OprO of Pseudomonas aeruginosa
Vinaya Kumar Golla et al.
JOURNAL OF PHYSICAL CHEMISTRY B (2022)
Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis
Christopher J. L. Murray et al.
LANCET (2022)
Molecular Characterization of WCK 5222 (Cefepime/Zidebactam)-Resistant Mutants Developed from a Carbapenem-Resistant Pseudomonas aeruginosa Clinical Isolate
Xiaolei Pan et al.
Microbiology Spectrum (2022)
Association of blaVIM-2, blaPDC-35, blaOXA-10, blaOXA-488 and blaVEB-9 β-Lactamase Genes with Resistance to Ceftazidime-Avibactam and Ceftolozane-Tazobactam in Multidrug-Resistant Pseudomonas aeruginosa
Mazen A. Sid Ahmed et al.
ANTIBIOTICS-BASEL (2022)
An Evidence-Based Multidisciplinary Approach Focused on Creating Algorithms for Targeted Therapy of Infection-Related Ventilator-Associated Complications (IVACs) Caused by Pseudomonas aeruginosa and Acinetobacter baumannii in Critically Ill Adult Patients
Milo Gatti et al.
ANTIBIOTICS-BASEL (2022)
Outcomes with Cefiderocol Treatment in Patients with Bacteraemia Enrolled into Prospective Phase 2 and Phase 3 Randomised Clinical Studies
David L. Paterson et al.
INFECTIOUS DISEASES AND THERAPY (2022)
Therapeutic Strategies for Emerging Multidrug-Resistant Pseudomonas aeruginosa
Ashlan J. Kunz Coyne et al.
INFECTIOUS DISEASES AND THERAPY (2022)
In Vitro Activity of Cefiderocol against US and European Gram-Negative Clinical Isolates Collected in 2020 as Part of the SENTRY Antimicrobial Surveillance Program
Dee Shortridge et al.
MICROBIOLOGY SPECTRUM (2022)
Azithromycin: An Underappreciated Quinolone-Sparing Oral Treatment for Pseudomonas aeruginosa Infections
Erlinda R. Ulloa et al.
ANTIBIOTICS-BASEL (2022)
In Vitro Activity of Imipenem/Relebactam and Ceftolozane/Tazobactam Against Clinical Isolates of Gram-negative Bacilli With Difficult-to-Treat Resistance and Multidrug-resistant Phenotypes-Study for Monitoring Antimicrobial Resistance Trends, United States 2015-2017
James A. Karlowsky et al.
CLINICAL INFECTIOUS DISEASES (2021)
A Randomized, Double-blind, Multicenter Trial Comparing Efficacy and Safety of Imipenem/Cilastatin/Relebactam Versus Piperacillin/Tazobactam in Adults With Hospital-acquired or Ventilator-associated Bacterial Pneumonia (RESTORE-IMI 2 Study)
Ivan Titov et al.
CLINICAL INFECTIOUS DISEASES (2021)
Cefiderocol as Rescue Therapy for Acinetobacter baumannii and Other Carbapenem-resistant Gram-negative Infections in Intensive Care Unit Patients
Marco Falcone et al.
CLINICAL INFECTIOUS DISEASES (2021)
Activity of β-lactam/taniborbactam (VNRX-5133) combinations against carbapenem-resistant Gram-negative bacteria
Shazad Mushtaq et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
Molecular mechanisms driving the in vivo development of OXA-10-mediated resistance to ceftolozane/tazobactam and ceftazidime/avibactam during treatment of XDR Pseudomonas aeruginosa infections
Jorge Arca-Suarez et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
Efficacy and safety of cefiderocol or best available therapy for the treatment of serious infections caused by carbapenem-resistant Gram-negative bacteria (CREDIBLE-CR): a randomised, open-label, multicentre, pathogen-focused, descriptive, phase 3 trial
Matteo Bassetti et al.
LANCET INFECTIOUS DISEASES (2021)
Cefiderocol versus high-dose, extended-infusion meropenem for the treatment of Gram-negative nosocomial pneumonia (APEKS-NP): a randomised, double-blind, phase 3, non-inferiority trial
Richard G. Wunderink et al.
LANCET INFECTIOUS DISEASES (2021)
Activity of Cefepime in Combination with the Novel β-Lactamase Inhibitor Taniborbactam (VNRX-5133) against Extended-Spectrum-β-Lactamase-Producing Isolates in In Vitro Checkerboard Assays
Wendy Kloezen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Evolution of Cefiderocol Non-Susceptibility in Pseudomonas aeruginosa in a Patient Without Previous Exposure to the Antibiotic
Ana Paula Streling et al.
CLINICAL INFECTIOUS DISEASES (2021)
Multicenter study of ceftolozane/tazobactam for treatment of Pseudomonas aeruginosa infections in critically ill patients
Barbara Balandin et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2021)
An update on cefepime and its future role in combination with novel beta-lactamase inhibitors for MDR Enterobacterales and Pseudomonas aeruginosa
Burcu Isler et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
The role of new carbapenem combinations in the treatment of multidrug-resistant Gram-negative infections
Emilio Bouza
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
It's Not Easy Being Green: A Narrative Review on the Microbiology, Virulence and Therapeutic Prospects of Multidrug-Resistant Pseudomonas aeruginosa
Payam Behzadi et al.
ANTIBIOTICS-BASEL (2021)
Susceptibility Testing Is Key for the Success of Cefiderocol Treatment: A Retrospective Cohort Study
Alexandre Bleibtreu et al.
MICROORGANISMS (2021)
In Vitro Susceptibility of Multidrug-Resistant Pseudomonas aeruginosa following Treatment-Emergent Resistance to Ceftolozane-Tazobactam
Abigail M. Rubio et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Infectious Diseases Society of America Guidance on the Treatment of Extended-Spectrum β-lactamase Producing Enterobacterales (ESBL-E), Carbapenem-Resistant Enterobacterales (CRE), and Pseudomonas aeruginosa with Difficult-to-Treat Resistance (DTR-P. aeruginosa)
Pranita D. Tamma et al.
CLINICAL INFECTIOUS DISEASES (2021)
In vitro activity of imipenem-relebactam against various resistance phenotypes/genotypes of Enterobacterales and Pseudomonas aeruginosa isolated from patients across Canada as part of the CANWARD study, 2016-2019
Andrew Walkty et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2021)
Activity of cefepime/zidebactam (WCK 5222) against 'problem' antibiotic-resistant Gram-negative bacteria sent to a national reference laboratory
Shazad Mushtaq et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections
Nicholas Rebold et al.
OPEN FORUM INFECTIOUS DISEASES (2021)
Cefiderocol: An Overview of Its in-vitro and in-vivo Activity and Underlying Resistant Mechanisms
Jiahui Yao et al.
FRONTIERS IN MEDICINE (2021)
Assessment of a PK/PD Target of Continuous Infusion Beta-Lactams Useful for Preventing Microbiological Failure and/or Resistance Development in Critically Ill Patients Affected by Documented Gram-Negative Infections
Milo Gatti et al.
ANTIBIOTICS-BASEL (2021)
Emergence of Resistance to Novel Cephalosporin-β-Lactamase Inhibitor Combinations through the Modification of the Pseudomonas aeruginosa MexCD-OprJ Efflux Pump
Maria A. Gomis-Font et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
In vitro antimicrobial susceptibility of clinical respiratory isolates to ceftazidime-avibactam and comparators (2016-2018)
D. Pierard et al.
BMC INFECTIOUS DISEASES (2021)
Continuous versus intermittent infusion of antibiotics in Gram-negative multidrug-resistant infections
Milo Gatti et al.
CURRENT OPINION IN INFECTIOUS DISEASES (2021)
In vitro activity of cefepime/zidebactam (WCK 5222) against recent Gram-negative isolates collected from high resistance settings of Greek hospitals
Sachin S. Bhagwat et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2021)
In vitro comparative activity of the new beta-lactamase inhibitor taniborbactam with cefepime or meropenem against Klebsiella pneumoniae and cefepime against Pseudomonas aeruginosa metallo-beta-lactamase-producing clinical isolates
Joseph Meletiadis et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2021)
In vitro evolution of cefepime/zidebactam (WCK 5222) resistance in Pseudomonas aeruginosa: dynamics, mechanisms, fitness trade-off and impact on in vivo efficacy
Isabel Barcelo et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
Activity of meropenem/vaborbactam and comparators against Gram-negative isolates from Eastern and Western European patients hospitalized with pneumonia including ventilator-associated pneumonia (2014-19)
Dee Shortridge et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2021)
Ceftolozane/Tazobactam and Imipenem/Relebactam Cross-Susceptibility Among Clinical Isolates of Pseudomonas aeruginosa From Patients With Respiratory Tract Infections in ICU and Non-ICU Wards-SMART United States 2017-2019
Sibylle H. Lob et al.
OPEN FORUM INFECTIOUS DISEASES (2021)
Review of Ceftazidime-Avibactam for the Treatment of Infections Caused by Pseudomonas aeruginosa
George L. Daikos et al.
ANTIBIOTICS-BASEL (2021)
Cefiderocol-Based Combination Therapy for Difficult-to-Treat Gram-Negative Severe Infections: Real-Life Case Series and Future Perspectives
Davide Fiore Bavaro et al.
ANTIBIOTICS-BASEL (2021)
Ceftazidime-Avibactam for the Treatment of Serious Gram-Negative Infections with Limited Treatment Options: A Systematic Literature Review
Alex Soriano et al.
INFECTIOUS DISEASES AND THERAPY (2021)
Real-life experience with compassionate use of cefiderocol for difficult-to-treat resistant Pseudomonas aeruginosa (DTR-P) infections
Marianna Meschiari et al.
JAC-ANTIMICROBIAL RESISTANCE (2021)
Antimicrobial activity of ceftazidime/avibactam, ceftolozane/tazobactam and comparator agents against Pseudomonas aeruginosa from cystic fibrosis patients
Helio S. Sader et al.
JAC-ANTIMICROBIAL RESISTANCE (2021)
In Vitro Activity of Cefepime-Zidebactam, Ceftazidime-Avibactam, and Other Comparators against Clinical Isolates of Enterobacterales, Pseudomonas aeruginosa, and Acinetobacter baumannii: Results from China Antimicrobial Surveillance Network (CHINET) in 2018
Yang Yang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2021)
Plazomicin: A New Aminoglycoside
Louis D. Saravolatz et al.
CLINICAL INFECTIOUS DISEASES (2020)
Ceftolozane/Tazobactam vs Polymyxin or Aminoglycoside-based Regimens for the Treatment of Drug-resistant Pseudomonas aeruginosa
Jason M. Pogue et al.
CLINICAL INFECTIOUS DISEASES (2020)
RESTORE-IMI 1: A Multicenter, Randomized, Double-blind Trial Comparing Efficacy and Safety of Imipenem/Relebactam vs Colistin Plus Imipenem in Patients With Imipenem-nonsusceptible Bacterial Infections
Johann Motsch et al.
CLINICAL INFECTIOUS DISEASES (2020)
Meropenem-nacubactam activity against AmpC-overproducing and KPC-expressing Pseudomonas aeruginosa in a neutropenic murine lung infection model
Tomefa E. Asempa et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
In vitro activity of imipenem/relebactam against Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples: SMART Surveillance United States 2015-2017
James A. Karlowsky et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2020)
Real-World Experience with Ceftolozane-Tazobactam for Multidrug-Resistant Gram-Negative Bacterial Infections
Sarah C. J. Jorgensen et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Activity of Meropenem-Vaborbactam against Bacterial Isolates Causing Pneumonia in Patients in US Hospitals during 2014 to 2018
Cecilia G. Carvalhaes et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Comparative Evaluation of the In Vitro Activities of WCK 5222 (Cefepime-Zidebactam) and Combination Antibiotic Therapies against Carbapenem-Resistant Pseudomonas aeruginosa
Elias M. Mullane et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
In vitro activity of imipenem-relebactam against resistant phenotypes of Enterobacteriaceae and Pseudomonas aeruginosa isolated from intraabdominal and urinary tract infection samples - SMART Surveillance Europe 2015-2017
Sibylle H. Lob et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2020)
Meropenem/vaborbactam: a next generation β-lactam β-lactamase inhibitor combination
Andrea Novelli et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2020)
The Battle Is on: New Beta-Lactams for the Treatment of Multidrug-Resistant Gram-Negative Organisms
Mandee Noval et al.
CURRENT INFECTIOUS DISEASE REPORTS (2020)
In vitro synergy of ceftolozane/tazobactam in combination with fosfomycin or aztreonam against MDR Pseudomonas aeruginosa
Gabriel T. Cuba et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
In vivo activity of human-simulated regimens of imipenem alone and in combination with relebactam against Pseudomonas aeruginosa in the murine thigh infection model
Sergio Reyes et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
Cefiderocol for extensively-drug resistant gram-negative bacterial infections: real-world experience from a case-series and review of the literature
Sandra Zingg et al.
Open Forum Infectious Diseases (2020)
Susceptibility trends of ceftolozane/tazobactam and comparators when tested against European Gram-negative bacterial surveillance isolates collected during 2012-18
Helio S. Sader et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2020)
In Vitro Activity of WCK 5222 (Cefepime-Zidebactam) against Worldwide Collected Gram-Negative Bacilli Not Susceptible to Carbapenems
James A. Karlowsky et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2020)
Pseudomonas aeruginosa epidemic high-risk clones and their association with horizontally-acquired β-lactamases: 2020 update
Ester del Barrio-Tofino et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2020)
Evaluating Cefiderocol in the Treatment of Multidrug-Resistant Gram-Negative Bacilli: A Review of the Emerging Data
Daniele Roberto Giacobbe et al.
INFECTION AND DRUG RESISTANCE (2020)
Clinical Experience with Ceftazidime-Avibactam for the Treatment of Infections due to Multidrug-Resistant Gram-Negative Bacteria Other than Carbapenem-Resistant Enterobacterales
Antonio Vena et al.
ANTIBIOTICS-BASEL (2020)
New beta-Lactam-beta-Lactamase Inhibitor Combinations
Dafna Yahav et al.
CLINICAL MICROBIOLOGY REVIEWS (2020)
Pharmacodynamic Attainment of the Synergism of Meropenem and Fosfomycin Combination against Pseudomonas aeruginosa Producing Metallo-β-Lactamase
James Albiero et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
The Novel β-Lactam Enhancer Zidebactam Augments the In Vivo Pharmacodynamic Activity of Cefepime in a Neutropenic Mouse Lung Acinetobacter baumannii Infection Model
S. S. Bhagwat et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Activity of ceftolozane/tazobactam against Pseudomonas aeruginosa and Enterobacterales isolates recovered from intensive care unit patients in Spain: The SUPERIOR multicentre study
Sergio Garcia-Fernandez et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Phylogenetic analysis of resistance to ceftazidime/avibactam, ceftolozane/tazobactam and carbapenems in piperacillin/tazobactam-resistant Pseudomonas aeruginosa from cystic fibrosis patients
Roxana Zamudio et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Efficacy of ceftolozane/tazobactam, alone and in combination with colistin, against multidrug-resistant Pseudomonas aeruginosa in an in vitro biofilm pharmacodynamic model
Joan Gomez-Junyent et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Activity of imipenem-relebactam against multidrug-resistant Pseudomonas aeruginosa from the United States - SMART 2015-2017
James A. Karlowsky et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2019)
Antibacterial effect of imipenem/relebactam on aerobic Gram-negative bacilli: in vitro simulations of 7 or 14 day human exposures
Alan R. Noel et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Activity of imipenem/relebactam against MDR Pseudomonas aeruginosa in Europe: SMART 2015-17
Sibylle H. Lob et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2019)
Ceftazidime-Avibactam in Combination With Fosfomycin: A Novel Therapeutic Strategy Against Multidrug-Resistant Pseudomonas aeruginosa
Krisztina M. Papp-Wallace et al.
JOURNAL OF INFECTIOUS DISEASES (2019)
Prevalence of in vitro synergistic antibiotic interaction between fosfomycin and nonsusceptible antimicrobials in carbapenem-resistant Pseudomonas aeruginosa
Lindsay M. Avery et al.
JOURNAL OF MEDICAL MICROBIOLOGY (2019)
Evaluation of the Synergy of Ceftazidime-Avibactam in Combination with Meropenem, Amikacin, Aztreonam, Colistin, or Fosfomycin against Well-Characterized Multidrug-Resistant Klebsiella pneumoniae and Pseudomonas aeruginosa
Sandra Mikhail et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
In vitro studies evaluating the activity of imipenem in combination with relebactam against Pseudomonas aeruginosa
Katherine Young et al.
BMC MICROBIOLOGY (2019)
Incremental clinical and economic burden of suspected respiratory infections due to multi-drug-resistant Pseudomonas aeruginosa in the United States
Y. P. Tabak et al.
JOURNAL OF HOSPITAL INFECTION (2019)
Challenging Antimicrobial Susceptibility and Evolution of Resistance (OXA-681) during Treatment of a Long-Term Nosocomial Infection Caused by a Pseudomonas aeruginosa ST175 Clone
Jorge Arca-Suarez et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Epidemiology and Treatment of Multidrug-Resistant and Extensively Drug-Resistant Pseudomonas aeruginosa Infections
Juan P. Horcajada et al.
CLINICAL MICROBIOLOGY REVIEWS (2019)
Strong correlation between the rates of intrinsically antibiotic-resistant species and the rates of acquired resistance in Gram-negative species causing bacteraemia, EU/EEA, 2016
Vincent Jarlier et al.
EUROSURVEILLANCE (2019)
Ceftolozane-tazobactam versus meropenem for treatment of nosocomial pneumonia (ASPECT-NP): a randomised, controlled, double-blind, phase 3, non-inferiority trial
Marin H. Kollef et al.
LANCET INFECTIOUS DISEASES (2019)
In Vitro Activity of Cefiderocol Against a Broad Range of Clinically Important Gram-negative Bacteria
Yoshinori Yamano
CLINICAL INFECTIOUS DISEASES (2019)
A Case-Control Study of Real-Life Experience with Ceftolozane-Tazobactam in Patients with Hematologic Malignancy and Pseudomonas aeruginosa Infection
Ana Fernandez-Cruz et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Activity of Meropenem-Vaborbactam against Pseudomonas aeruginosa and Acinetobacter baumannii in a Neutropenic Mouse Thigh Infection Model
Mojgan Sabet et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
In Vivo Efficacy of Humanized WCK 5222 (Cefepime-Zidebactam) Exposures against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Thigh Model
Safa S. Almarzoky Abuhussain et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
VNRX-5133 (Taniborbactam), a Broad-Spectrum Inhibitor of Serine- and Metallo-β-Lactamases, Restores Activity of Cefepime in Enterobacterales and Pseudomonas aeruginosa
Jodie C. Hamrick et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2019)
Ceftolozane/tazobactam for the treatment of serious Pseudomonas aeruginosa infections: a multicentre nationwide clinical experience
Matteo Bassetti et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2019)
Attributable deaths and disability-adjusted life-years caused by infections with antibiotic-resistant bacteria in the EU and the European Economic Area in 2015: a population-level modelling analysis
Alessandro Cassini et al.
LANCET INFECTIOUS DISEASES (2019)
Real-World Experience With Ceftazidime-Avibactam for Multidrug-Resistant Gram-Negative Bacterial Infections
Sarah C. J. Jorgensen et al.
OPEN FORUM INFECTIOUS DISEASES (2019)
Antibacterial activity of ceftolozane/tazobactam alone and in combination with other antimicrobial agents against MDR Pseudomonas aeruginosa
Marguerite L. Monogue et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
In Vitro Activity of Imipenem-Relebactam against Clinical Isolates of Gram-Negative Bacilli Isolated in Hospital Laboratories in the United States as Part of the SMART 2016 Program
James A. Karlowsky et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Difficult-to-Treat Resistance in Gram-negative Bacteremia at 173 US Hospitals: Retrospective Cohort Analysis of Prevalence, Predictors, and Outcome of Resistance to All First-line Agents
Sameer S. Kadri et al.
CLINICAL INFECTIOUS DISEASES (2018)
Ceftolozane/tazobactam: place in therapy
Daniele Roberto Giacobbe et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2018)
In vitro activity of imipenem/relebactam against Gram-negative ESKAPE pathogens isolated in 17 European countries: 2015 SMART surveillance programme
James A. Kartowsky et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Clinical activity of ceftazidime/avibactam against MDR Enterobacteriaceae and Pseudomonas aeruginosa: pooled data from the ceftazidime/avibactam Phase III clinical trial programme
Gregory G. Stone et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2018)
Ceftazidime-avibactam versus meropenem in nosocomial pneumonia, including ventilator-associated pneumonia (REPROVE): a randomised, double-blind, phase 3 non-inferiority trial
Antoni Torres et al.
LANCET INFECTIOUS DISEASES (2018)
Assessment of the In Vivo Efficacy of WCK 5222 (Cefepime-Zidebactam) against Carbapenem-Resistant Acinetobacter baumannii in the Neutropenic Murine Lung Infection Model
Lindsay M. Avery et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Activity of imipenem/relebactam against Pseudomonas aeruginosa with antimicrobial-resistant phenotypes from seven global regions: SMART 2015-2016
James A. Karlowsky et al.
JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE (2018)
Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: A Multicenter Study
Jason C. Gallagher et al.
OPEN FORUM INFECTIOUS DISEASES (2018)
In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, against Carbapenem-Nonsusceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014 to 2016
Meredith A. Hackel et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2018)
Imipenem-Relebactam and Meropenem-Vaborbactam: Two Novel Carbapenem-beta-Lactamase Inhibitor Combinations
George G. Zhanel et al.
DRUGS (2018)
A randomised, double-blind, phase 3 study comparing the efficacy and safety of ceftazidime/avibactam plus metronidazole versus meropenem for complicated intra-abdominal infections in hospitalised adults in Asia
Xinyu Qin et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2017)
AmpC β-lactamase induction by avibactam and relebactam
David M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Activity of ceftolozane/tazobactam against surveillance and 'problem' Enterobacteriaceae, Pseudomonas aeruginosa and non-fermenters from the British Isles
David M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Pseudomonas aeruginosa Lifestyle: A Paradigm for Adaptation, Survival, and Persistence
M. Fata Moradali et al.
FRONTIERS IN CELLULAR AND INFECTION MICROBIOLOGY (2017)
In Vivo Emergence of Resistance to Novel Cephalosporin-β-Lactamase Inhibitor Combinations through the Duplication of Amino Acid D149 from OXA-2 β-Lactamase (OXA-539) in Sequence Type 235 Pseudomonas aeruginosa
Pablo A. Fraile-Ribot et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
Ceftolozane-Tazobactam for the Treatment of Multidrug-Resistant Pseudomonas aeruginosa Infections: Clinical Effectiveness and Evolution of Resistance
Ghady Haidar et al.
CLINICAL INFECTIOUS DISEASES (2017)
WCK 5107 (Zidebactam) and WCK 5153 Are Novel Inhibitors of PBP2 Showing Potent β-Lactam Enhancer Activity against Pseudomonas aeruginosa, Including Multidrug-Resistant Metallo-β-Lactamase-Producing High-Risk Clones
Bartolome Moya et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
In Vitro Activity of Imipenem-Relebactam against Gram-Negative ESKAPE Pathogens Isolated by Clinical Laboratories in the United States in 2015 (Results from the SMART Global Surveillance Program)
Sibylle H. Lob et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
WCK 5222 (Cefepime-Zidebactam) Antimicrobial Activity against Clinical Isolates of Gram-Negative Bacteria Collected Worldwide in 2015
Helio S. Sader et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2017)
In Vitro Susceptibility of Global Surveillance Isolates of Pseudomonas aeruginosa to Ceftazidime-Avibactam (INFORM 2012 to 2014)
Wright W. Nichols et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Evaluation of the In Vitro Activity of Ceftazidime-Avibactam and Ceftolozane-Tazobactam against Meropenem-Resistant Pseudomonas aeruginosa Isolates
Deanna J. Buehrle et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Ceftazidime-avibactam Versus Doripenem for the Treatment of Complicated Urinary Tract Infections, Including Acute Pyelonephritis: RECAPTURE, a Phase 3 Randomized Trial Program
Florian M. Wagenlehner et al.
CLINICAL INFECTIOUS DISEASES (2016)
Efficacy and Safety of Ceftazidime-Avibactam Plus Metronidazole Versus Meropenem in the Treatment of Complicated Intra-abdominal Infection: Results From a Randomized, Controlled, Double-Blind, Phase 3 Program
John E. Mazuski et al.
CLINICAL INFECTIOUS DISEASES (2016)
Ceftazidime/Avibactam and Ceftolozane/Tazobactam: Second-generation β-Lactam/β-Lactamase Inhibitor Combinations
David van Duin et al.
CLINICAL INFECTIOUS DISEASES (2016)
In vitro activity of ceftolozane/tazobactam against clinical isolates of Pseudomonas aeruginosa in the planktonic and biofilm states
Antonio L. Velez Perez et al.
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE (2016)
Ceftazidime-avibactam or best available therapy in patients with ceftazidime-resistant Enterobacteriaceae and Pseudomonas aeruginosa complicated urinary tract infections or complicated intra-abdominal infections (REPRISE): a randomised, pathogen-directed, phase 3 study
Yehuda Carmeli et al.
LANCET INFECTIOUS DISEASES (2016)
Activity of Imipenem with Relebactam against Gram-Negative Pathogens from New York City
Amabel Lapuebla et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Activity of Meropenem Combined with RPX7009, a Novel beta-Lactamase Inhibitor, against Gram-Negative Clinical Isolates in New York City
Amabel Lapuebla et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI)
Joseph Solomkin et al.
CLINICAL INFECTIOUS DISEASES (2015)
Ceftolozane-tazobactam compared with levofloxacin in the treatment of complicated urinary-tract infections, including pyelonephritis: a randomised, double-blind, phase 3 trial (ASPECT-cUTI)
Florian M. Wagenlehner et al.
LANCET (2015)
Unexpected Challenges in Treating Multidrug-Resistant Gram-Negative Bacteria: Resistance to Ceftazidime-Avibactam in Archived Isolates of Pseudomonas aeruginosa
Marisa L. Winkler et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2015)
Bacterial contamination of inanimate surfaces and equipment in the intensive care unit
Vincenzo Russotto et al.
JOURNAL OF INTENSIVE CARE (2015)
Mutation-Driven β-Lactam Resistance Mechanisms among Contemporary Ceftazidime-Nonsusceptible Pseudomonas aeruginosa Isolates from US Hospitals
Mariana Castanheira et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2014)
Activity of MK-7655 combined with imipenem against Enterobacteriaceae and Pseudomonas aeruginosa
David M. Livermore et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2013)
Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance
A. -P. Magiorakos et al.
CLINICAL MICROBIOLOGY AND INFECTION (2012)
Structural requirements for the stability of novel cephalosporins to AmpC β-lactamase based on 3D-structure
Kenji Murano et al.
BIOORGANIC & MEDICINAL CHEMISTRY (2008)
Involvement of the MexXY-OprM efflux system in emergence of cefepime resistance in clinical strains of Pseudomonas aeruginosa
D Hocquet et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Effect of β-lactam antibiotics on the in vitro development of resistance in Pseudomonas aeruginosa
H Carsenti-Etesse et al.
CLINICAL MICROBIOLOGY AND INFECTION (2001)
Share Paper
